PDT Partners LLC boosted its position in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) by 22.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 191,952 shares of the biopharmaceutical company’s stock after purchasing an additional 34,665 shares during the quarter. PDT Partners LLC owned about 0.38% of Tetraphase Pharmaceuticals worth $1,369,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Balyasny Asset Management LLC lifted its stake in Tetraphase Pharmaceuticals by 13.2% in the 2nd quarter. Balyasny Asset Management LLC now owns 246,300 shares of the biopharmaceutical company’s stock worth $1,756,000 after purchasing an additional 28,800 shares in the last quarter. Numeric Investors LLC lifted its stake in Tetraphase Pharmaceuticals by 1,363.3% in the 2nd quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock worth $5,379,000 after purchasing an additional 702,812 shares in the last quarter. Voya Investment Management LLC lifted its stake in Tetraphase Pharmaceuticals by 17.8% in the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,104 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Tetraphase Pharmaceuticals by 73.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,101,255 shares of the biopharmaceutical company’s stock worth $7,853,000 after purchasing an additional 466,955 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new stake in Tetraphase Pharmaceuticals in the 2nd quarter worth approximately $147,000. Institutional investors and hedge funds own 41.73% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Tetraphase Pharmaceuticals, Inc. (TTPH) Holdings Increased by PDT Partners LLC” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/tetraphase-pharmaceuticals-inc-ttph-holdings-increased-by-pdt-partners-llc/1610152.html.

Shares of Tetraphase Pharmaceuticals, Inc. (TTPH) opened at 7.75 on Thursday. Tetraphase Pharmaceuticals, Inc. has a 52-week low of $3.11 and a 52-week high of $9.93. The stock’s 50 day moving average is $6.68 and its 200 day moving average is $7.29. The stock’s market cap is $395.66 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. During the same quarter in the prior year, the company posted ($0.47) EPS. Tetraphase Pharmaceuticals’s revenue was up 28.2% compared to the same quarter last year. Equities research analysts forecast that Tetraphase Pharmaceuticals, Inc. will post ($2.54) earnings per share for the current year.

In related news, insider Jacques Dumas sold 7,155 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $5.86, for a total transaction of $41,928.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 5.50% of the stock is currently owned by corporate insiders.

Several analysts have issued reports on the stock. BMO Capital Markets increased their target price on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a research note on Wednesday. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. HC Wainwright began coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They set a “buy” rating and a $15.00 price objective on the stock. Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the company from $8.00 to $15.00 in a research report on Wednesday, July 26th. Finally, BidaskClub upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $12.96.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.